US Health Advisers Endorse Johnson & Johnson COVID-19 Vaccine

Strategic Insights -

US health advisers have unanimously endorsed a one-dose COVID-19 vaccine from Johnson & Johnson, making the nation on the cusp of adding an easier-to-use option to fight the pandemic. The FDA is expected to follow the recommendation, and vaccinations are picking up speed, but new supplies are urgently needed to stay ahead of a mutating virus that has killed over 500,000 Americans. The Johnson & Johnson vaccine provides 85% protection against severe COVID-19 after a single dose and 66% against moderate cases.

Key Takeaways:

  • The FDA panel voted unanimously that the benefits of the vaccine outweighed the risks for adults, with 86% of participants showing some form of immune response.
  • The Johnson & Johnson vaccine can be stored at refrigerator temperatures for up to three months, making it easier to handle than the previous vaccines, which must be frozen.
  • The vaccine protects against severe COVID-19 after a single shot, but its effectiveness against moderate cases is around 66%.
  • The company has said it can deliver 20 million doses by the end of March and a total of 100 million by the end of June.
  • Johnson & Johnson's vaccine was tested in the US, Latin America, and South Africa at a time when more contagious mutated versions of the virus were spreading.
  • Experts fear that the lower number of protection could feed public perceptions that J&J's shot is a "second-tier vaccine."
  • The FDA reported that, just like its predecessors, the J&J shot offers strong protection against hospitalization and death.
  • The company is also studying whether a second dose boosts protection, but some experts warn that launching a two-dose version might cause problems.

Statistics:

  • 47 million people in the US (14% of the population) have received at least one shot of the two-dose vaccines from Pfizer and Moderna.
  • 85% protection against severe COVID-19 after a single dose of the Johnson & Johnson vaccine.
  • 66% effectiveness against moderate cases after a single dose of the Johnson & Johnson vaccine.
  • 20 million doses of Johnson & Johnson's vaccine are expected to be delivered by the end of March.
  • 100 million doses of Johnson & Johnson's vaccine are expected to be delivered by the end of June.
  • 500,000 Americans have been killed by COVID-19.

Sources:

  • Associated Press: "US Health Advisers Endorse Johnson & Johnson COVID-19 Vaccine"
  • Johnson & Johnson: "Statement on FDA Advisory Committee Vote to Authorize Johnson & Johnson's Single-Shot COVID-19 Vaccine"
  • Centers for Disease Control and Prevention: "Interim Results of the Phase 3 Johnson & Johnson COVID-19 Vaccine Study"
  • World Health Organization: "COVID-19 Vaccine: Johnson & Johnson Single-Dose Vaccine"
  • AstraZeneca: "COVID-19 Vaccine Candidate AZD1222: Efficacy and Safety Results from the Phase 3 trials"